Participants received 3 initial monthly ranibizumab 0.5 mg injections ( day 0 to month 2 ) , followed by individualized best-corrected visual acuity ( BCVA ) and optical coherence tomography-guided re-treatment with monthly ( months 3-5 ) and subsequent bimonthly follow-up ( months 6-18 ) .